Welcome to LookChem.com Sign In|Join Free
  • or
3,4-dihydrobenzo[f][1,4]thiazepin-5(2H)-one is a thiazepine derivative, a type of organic compound characterized by a seven-membered heterocyclic ring with four carbon atoms, one sulfur atom, and two nitrogen atoms. This complex chemical compound is recognized for its pharmaceutical properties and is a promising candidate in the development of potential drug candidates due to its potential activities as an antipsychotic, antidepressant, and anxiolytic agent.

14944-00-4

Post Buying Request

14944-00-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

14944-00-4 Usage

Uses

Used in Pharmaceutical Industry:
3,4-dihydrobenzo[f][1,4]thiazepin-5(2H)-one is used as a potential drug candidate for the treatment of psychiatric disorders. Its application is based on its possible activities as an antipsychotic, antidepressant, and anxiolytic agent, which make it a valuable asset in the development of new therapeutic options for various mental health conditions.
Used in Research and Development:
3,4-dihydrobenzo[f][1,4]thiazepin-5(2H)-one is utilized in ongoing research to further understand its biological and therapeutic effects. This research is crucial for elucidating the compound's potential mechanisms of action and its efficacy in treating psychiatric disorders, thereby contributing to the advancement of pharmaceutical science and medicine.

Check Digit Verification of cas no

The CAS Registry Mumber 14944-00-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,9,4 and 4 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 14944-00:
(7*1)+(6*4)+(5*9)+(4*4)+(3*4)+(2*0)+(1*0)=104
104 % 10 = 4
So 14944-00-4 is a valid CAS Registry Number.

14944-00-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 3,4-dihydro-2H-1,4-benzothiazepin-5-one

1.2 Other means of identification

Product number -
Other names RW2678

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:14944-00-4 SDS

14944-00-4Relevant academic research and scientific papers

Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors

Zheng, Xiufang,Liang, Chungen,Wang, Lisha,Wang, Baoxia,Liu, Yongfu,Feng, Song,Wu, Jim Zhen,Gao, Lu,Feng, Lichun,Chen, Li,Guo, Tao,Shen, Hong C.,Yun, Hongying

, p. 10228 - 10241 (2018)

A novel benzoazepinequnoline (BAQ) series was discovered as RSV fusion inhibitors. BAQ series originated from compound 2, a hit from similarity-based virtual screening. In SAR exploration, benzoazepine allowed modifications in the head moiety. Benzylic sulfonyl on benzoazepine and 6-Me on quinoline were crucial for good anti-RSV activity. Although the basic amine in the head portion was crucial for anti-RSV activity, the attenuated basicity was required to reduce Vss. Introducing oxetane to the head portion led to discovery of compound 1, which demonstrated single-digit nM anti-RSV activity against different RSV strains, reasonable oral exposure in plasma, and 78-fold higher exposure in lung. Compound 1 also displayed 1 log viral reduction in a female BALB/c mice RSV model by b.i.d. oral dosing at 12.5 mg/kg. A single resistant mutant at L138F in fusion protein proved compound 1 to be a RSV fusion inhibitor.

Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N- methyltransferase

Grunewald, Gary L.,Dahanukar, Vilas H.,Ching, Piao,Criscione, Kevin R.

, p. 3539 - 3546 (1996)

In the search for potent and selective inhibitors of the enzyme phenylethanolamine N-methyltransferase (PNMT; EC 2.1.1.28), we examined the effect of ring size or an additional heteroatom in the conformationally- restricted benzylamine-type PNMT inhibitors. Based on semiempirical calculations (MNDO) and molecular modeling studies, PNMT-inhibitory activity of these compounds seemed to be dependent on (a) the torsion angle between the plane of the aromatic ring and the endo N atom lone pair (τ2 angle), with the optimal value of τ2 being about -75°, and (b) the amount of steric bulk about the 3-position of 1,2,3,4-tetrahydroisoquinoline (5, THIQ). 2,3,4,5-Tetrahydro-1H-2-benzazepine (6) was found to have the highest selectivity (PNMT K(i) = 3.34 μM, α2 K(i) = 11 μM, selectivity = 3.2) as compared to other homologues of THIQ (PNMT K(i) = 9.67 μM, α2 K(i) = 0.35 μM, selectivity = 0.036). The higher PNMT-inhibitory activity of 6 was attributed to favorable steric interactions of the puckered methylene groups in the putative bioactive conformation of 6 at the PNMT active site, whereas unfavorable interactions of these puckered methylene groups at the α2- adrenoceptor were thought to be the cause of reduced α2 affinity of 6. No further enhancement of the selectivity of the benzazepine ring system could be obtained via introduction of a second heteroatom (N, O, S) at the 5- position in this ring system.

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

-

Paragraph 0048; 0051, (2021/02/25)

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE

-

Paragraph 0104; 0105, (2013/04/13)

The invention relates to the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2 and X are as defined in the description and claims, which are useful for the treatment or prophylaxis of RSV infection.

COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE

-

Page/Page column 15-16, (2013/04/25)

A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1, R2 and X are as defined in description and in claims, can be used as a medicament.

Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient

-

, (2008/06/13)

A benzene-fused heteroring derivative of formula (I) 1, wherein all symbols are the same as described in the specification, and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is

Base-promoted aminoethylation of thiols with 2-oxazolidinones: A simple synthesis of 2-aminoethyl sulfides

Ishibashi, Hiroyuki,Uegaki, Masayuki,Sakai, Manami,Takeda, Yoshifumi

, p. 2115 - 2120 (2007/10/03)

A simple synthesis of 2-aminoethyl sulfides using a base-promoted reaction of 2-oxazolidinones with thiols is described. An application of this method to the synthesis of chiral 2-aminoethyl sulfides and sulfur-containing heterocyclic compounds is also presented.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 14944-00-4